Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer
JAMA · 2024
DOI: 10.1001/jama.2024.15491 ↗Kurz gefasst
Leserbrief in der Zeitschrift JAMA, 2024. Verfasst von Fausto Petrelli und 1 weiteren Autor:innen. Beteiligte Einrichtung: ASST Bergamo Ovest, Treviglio (BG), Italy. Hauptthemen laut MEDLINE: Aspirin, Breast Neoplasms. Die Arbeit nennt 4 Literaturangaben.
Abstract (Originalsprache)
To the Editor A recent study1 that investigated the effects of aspirin on breast cancer recurrence in high-risk patients with nonmetastatic disease concluded that daily aspirin therapy did not reduce breast cancer recurrence or improve survival. We have some comments about this study.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- ASST Bergamo Ovest, Treviglio (BG), Italy.
- Casa di cura Igea, Milan, Italy.
Zitieren
APA
Petrelli, F., & Ghidini, A. (2024). Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer. JAMA. https://doi.org/10.1001/jama.2024.15491
Vancouver
Petrelli F, Ghidini A. Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer. JAMA. 2024. doi:10.1001/jama.2024.15491
BibTeX
@article{Petrelli2024,
author = {Petrelli, Fausto and Ghidini, Antonio},
title = {Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer},
journal = {JAMA},
year = {2024},
doi = {10.1001/jama.2024.15491}
}
EUVIMED